BLI Banque de Luxembourg Investments Acquires New Position in Bristol-Myers Squibb (NYSE:BMY)

BLI Banque de Luxembourg Investments bought a new stake in Bristol-Myers Squibb (NYSE:BMY - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 247,000 shares of the biopharmaceutical company's stock, valued at approximately $13,848,000.

Other large investors have also made changes to their positions in the company. World Investment Advisors LLC lifted its stake in shares of Bristol-Myers Squibb by 18.7% during the third quarter. World Investment Advisors LLC now owns 44,106 shares of the biopharmaceutical company's stock valued at $2,282,000 after acquiring an additional 6,954 shares during the period. Principal Financial Group Inc. grew its position in shares of Bristol-Myers Squibb by 4.4% during the 3rd quarter. Principal Financial Group Inc. now owns 2,458,536 shares of the biopharmaceutical company's stock worth $127,205,000 after buying an additional 102,790 shares during the period. GAMMA Investing LLC lifted its holdings in Bristol-Myers Squibb by 22.0% in the fourth quarter. GAMMA Investing LLC now owns 33,418 shares of the biopharmaceutical company's stock valued at $1,890,000 after buying an additional 6,032 shares during the period. Pensionfund Sabic boosted its stake in Bristol-Myers Squibb by 32.8% in the fourth quarter. Pensionfund Sabic now owns 40,500 shares of the biopharmaceutical company's stock valued at $2,291,000 after acquiring an additional 10,000 shares during the last quarter. Finally, CWA Asset Management Group LLC raised its position in shares of Bristol-Myers Squibb by 27.5% during the 4th quarter. CWA Asset Management Group LLC now owns 111,149 shares of the biopharmaceutical company's stock valued at $6,287,000 after acquiring an additional 23,957 shares during the last quarter. Institutional investors own 76.41% of the company's stock.

Bristol-Myers Squibb Stock Performance

NYSE:BMY traded up $0.06 during mid-day trading on Wednesday, hitting $47.63. The stock had a trading volume of 15,857,611 shares, compared to its average volume of 13,025,287. The company's 50 day simple moving average is $55.31 and its 200 day simple moving average is $56.33. The stock has a market cap of $96.94 billion, a price-to-earnings ratio of -10.78, a PEG ratio of 2.07 and a beta of 0.39. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $63.33.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.50 by $0.30. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The company had revenue of $11.20 billion during the quarter, compared to analysts' expectations of $10.77 billion. During the same quarter last year, the company posted ($4.40) EPS. Bristol-Myers Squibb's quarterly revenue was down 5.6% compared to the same quarter last year. On average, equities research analysts forecast that Bristol-Myers Squibb will post 6.74 earnings per share for the current year.

Bristol-Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, May 1st. Investors of record on Friday, April 4th were given a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a yield of 5.21%. The ex-dividend date of this dividend was Friday, April 4th. Bristol-Myers Squibb's dividend payout ratio is 92.88%.

Insider Activity

In related news, EVP Samit Hirawat acquired 4,250 shares of the company's stock in a transaction on Friday, April 25th. The stock was purchased at an average cost of $47.58 per share, with a total value of $202,215.00. Following the acquisition, the executive vice president now directly owns 83,513 shares of the company's stock, valued at approximately $3,973,548.54. The trade was a 5.36 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.09% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Piper Sandler started coverage on Bristol-Myers Squibb in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $65.00 price objective for the company. Wells Fargo & Company lifted their price objective on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an "equal weight" rating in a research note on Friday, February 7th. William Blair reiterated a "market perform" rating on shares of Bristol-Myers Squibb in a report on Friday, April 25th. Truist Financial upped their price objective on shares of Bristol-Myers Squibb from $62.00 to $65.00 and gave the company a "buy" rating in a research report on Wednesday, January 8th. Finally, Jefferies Financial Group reduced their target price on Bristol-Myers Squibb from $70.00 to $68.00 and set a "buy" rating on the stock in a report on Wednesday, April 23rd. Two analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have given a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $58.00.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.